- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Geroscience and Alzheimer’s Disease Drug Development ; volume:10 ; number:4 ; day:24 ; month:10 ; year:2023 ; pages:620-632 ; date:11.2023
The journal of prevention of Alzheimer's disease ; 10, Heft 4 (24.10.2023), 620-632, 11.2023
- Creator
-
Cummings, Jeffrey
Osse, A. M. Leisgang
Kinney, J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2023.103
- URN
-
urn:nbn:de:101:1-2024011208521124534915
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cummings, Jeffrey
- Osse, A. M. Leisgang
- Kinney, J.
- SpringerLink (Online service)
Other Objects (12)
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Advances in Drug Therapy for Alzheimer’s Disease
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Advances in Drug Therapy for Alzheimer’s Disease
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Advances in Drug Therapy for Alzheimer’s Disease
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies